Pharmaceuticals

Preventive Vaccines Market to Reach $106.47 Billion by 2029, Growing at a CAGR of 6.9%

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Preventive Vaccines Industry Expected To Reach By 2029, Starting From 2025 Levels?

The preventive vaccines market size has experienced robust growth in recent years. This market is projected to expand from $75.94 billion in 2024 to $81.39 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Historically, this expansion has been driven by increasing government funding, rising awareness of infectious diseases, a rise in global immunization programs, increasing technological advancements in vaccine development, and rising demand for childhood immunization.

The preventive vaccines market is poised for significant expansion in the coming years. Its valuation is projected to reach $106.47 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is fueled by several factors, including escalating investment in vaccine research, the increasing occurrence of infectious diseases, a rising need for personalized vaccines, more government initiatives and backing, and the wider uptake of cutting-edge vaccine technologies. Key trends anticipated within this period encompass progress in mRNA vaccine technology, the development of sophisticated delivery systems, breakthroughs in nanoparticle-based vaccines, the incorporation of artificial intelligence into vaccine research, and improvements in cold chain logistics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Which Drivers Are Shaping The Preventive Vaccines Industry’s Market Share?

The anticipated expansion of the preventive vaccines market is linked to the growing occurrence of infectious diseases. These diseases are defined as ailments resulting from pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via the surroundings. Factors like escalating urbanization, widespread global travel, and resistance to antimicrobials contribute to the heightened incidence of infectious diseases, making their spread quicker and control more challenging. Preventive vaccines assist in managing infectious diseases by prompting the immune system to identify and combat pathogens prior to infection, consequently lowering the frequency and spread of illnesses. As an illustration, a report in July 2024 from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2022, infectious diseases were responsible for more than 15,770 fatalities in Australia, with lower respiratory infections comprising a third of these non-notifiable disease-related deaths. Consequently, the rising occurrence of infectious diseases is a key factor propelling the expansion of the preventive vaccines market.

What Are The Major Segment Categories Driving The Preventive Vaccines Market Growth?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Long-Term Trends Will Shape The Future Growth Of The Preventive Vaccines Industry?

Leading companies within the preventive vaccines market are concentrating on progress in vaccine technology, including advanced mRNA technology platforms, to boost vaccine effectiveness, improve safety profiles, facilitate quicker development and production, and offer broader defense against evolving variants of infectious diseases. Advanced mRNA technology platforms are sophisticated techniques employing messenger RNA to instruct cells to generate specific proteins, initiating a targeted immune response. For example, in March 2025, Moderna Inc., a US-based biotechnology firm, declared FDA clearance for mNEXSPIKE (mRNA-1283), a novel COVID-19 vaccine. It is approved for adults aged 65 and older and individuals aged 12–64 who have one or more CDC-defined risk factors. The introduction of mNEXSPIKE represents a considerable leap in next-generation mRNA vaccine technology, providing enhanced stability and simpler storage compared to previous iterations. This innovation is anticipated to improve vaccine availability and delivery, especially in underserved and remote regions.

Who Are The Primary Competitors In The Global Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2025, By The Business Research Company

Probiotics Dietary Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

Probiotics Food And Cosmetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-food-and-cosmetics-global-market-report

Animal Antibiotics And Antimicrobials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-antibiotics-and-antimicrobials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795